查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1729537

日本口服抗糖尿病药物市场报告（依药物类型（双胍类、α-葡萄糖苷酶抑制剂、多巴胺D2受体激动剂、SGLT-2抑制剂、DPP-4抑制剂、磺酰脲类、格列奈类））及地区 2025-2033

Japan Oral Anti-Diabetic Drug Market Report by Drug (Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 Receptor Agonist, SGLT-2 inhibitors, DPP-4 inhibitors, Sulfonylureas, Meglitinides), and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 121 Pages | 商品交期: 5-7个工作天内

价格
简介目录

2024年，日本口服抗糖尿病药物市场规模达24亿美元。展望未来， IMARC Group预计到2033年市场规模将达到37亿美元，2025-2033年期间的成长率（CAGR）为4.42%。由于生活方式的改变和肥胖率的上升等因素，糖尿病盛行率的上升是推动市场成长的主要因素。

口服抗糖尿病药物是第 2 型糖尿病治疗的关键，是一种用于调节身体抵抗胰岛素作用或无法产生足够胰岛素的个体的血糖水平的药物。虽然注射胰岛素仍然是糖尿病的主要治疗方法，但口服抗糖尿病药物提供了一种非侵入性的替代方法，并且通常作为阻止疾病进展的第一道防线。这些药物透过各种机制发挥作用，例如刺激胰臟产生更多的胰岛素，减少肝臟的葡萄糖产生，或改善身体组织的胰岛素敏感性。

日本口服抗糖尿病药物市场趋势：

日本口服抗糖尿病药物市场是其医疗保健产业的重要部分，反映了该国先进的医学研究能力和人口挑战。随着人口老化和都市化进程加快，包括第 2 型糖尿病在内的生活方式疾病明显增加。区域市场的一个独特驱动力是对研发活动的高度重视。 DPP-4 抑制剂和 SGLT2 抑制剂等创新药物的批准不仅扩大了治疗选择，而且还改善了血糖控制并减少了副作用。影响市场的另一个趋势是人们对个人化医疗的倾向日益增强。人们意识到糖尿病在个体上的表现不同，开始推动根据遗传、环境和生活方式因素制定个人化治疗方案。因此，使用两种或两种以上抗糖尿病药物的联合疗法越来越受到人们的关注，以实现更好的血糖控制。此外，日本政府在医疗保健方面采取积极态度，推行定期健康检查和早期发现的政策，间接促进了口服抗糖尿病药物市场的发展。透过强调预防措施和及时干预，该国不仅解决了眼前的健康需求，而且还减轻了与糖尿病併发症相关的长期医疗成本。除此之外，预计治疗方式的引入将在预测期内推动市场成长。

日本口服抗糖尿病药物市场细分：

药物洞察：

  • 双胍类
    • 二甲双胍
  • α-葡萄糖苷酶抑制剂
  • 多巴胺D2受体激动剂
    • 溴隐亭
  • SGLT-2抑制剂
    • Invokana（卡格列净）
    • Jardiance（恩格列净）
    • Farxiga/Forxiga（达格列净）
    • 舒格列净（伊普拉格列净）
  • DPP-4抑制剂
    • 沙格列汀（Onglyza）
    • Tradjenta（利格列汀）
    • Vipidia/Nesina（阿格列汀）
    • Galvus（维格列汀）
  • 磺酰脲类药物
  • 格列奈类

竞争格局：

市场研究报告也对竞争格局进行了全面的分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪表板和公司评估象限等竞争分析。此外，也提供了所有主要公司的详细资料。

本报告回答的关键问题：

  • 日本口服抗糖尿病药物市场目前表现如何？未来几年将如何表现？
  • COVID-19 对日本口服抗糖尿病药物市场有何影响？
  • 日本口服抗糖尿病药物市场按药物类型划分是怎样的？
  • 日本口服抗糖尿病药物市场的价值链分为哪些阶段？
  • 日本口服抗糖尿病药物的关键驱动因素和挑战是什么？
  • 日本口服抗糖尿病药物市场的结构是怎么样的？主要参与者是谁？
  • 日本口服抗糖尿病药物市场的竞争程度如何？

本报告回答的关键问题：

  • 日本口服抗糖尿病药物市场目前表现如何？未来几年将如何表现？
  • COVID-19 对日本口服抗糖尿病药物市场有何影响？
  • 日本口服抗糖尿病药物市场按药物类型划分是怎样的？
  • 日本口服抗糖尿病药物市场的价值链分为哪些阶段？
  • 日本口服抗糖尿病药物的关键驱动因素和挑战是什么？
  • 日本口服抗糖尿病药物市场的结构是怎么样的？主要参与者是谁？
  • 日本口服抗糖尿病药物市场的竞争程度如何？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：日本口服抗糖尿病药物市场－简介

  • 概述
  • 市场动态
  • 产业趋势
  • 竞争情报

第五章：日本口服抗糖尿病药物市场格局

  • 历史与当前市场趋势（2019-2024）
  • 市场预测（2025-2033）

第六章：日本口服抗糖尿病药物市场-细分：依药物

  • 双胍类
    • 概述
    • 市场区隔
      • 二甲双胍
  • α-葡萄糖苷酶抑制剂
    • 概述
  • 多巴胺D2受体激动剂
    • 概述
    • 市场区隔
      • 溴隐亭
  • SGLT-2抑制剂
    • 概述
    • 市场区隔
      • Invokana（卡格列净）
      • Jardiance（恩格列净）
      • Farxiga/Forxiga（达格列净）
      • 舒格列净（伊普拉格列净）
  • DPP-4抑制剂
    • 概述
    • 市场区隔
      • 沙格列汀（Onglyza）
      • Tradjenta（利格列汀）
      • Vipidia/Nesina（阿格列汀）
      • Galvus（维格列汀）
  • 磺酰脲类药物
    • 概述
  • 格列奈类
    • 概述

第七章：日本口服抗糖尿病药物市场－竞争格局

  • 概述
  • 市场结构
  • 市场参与者定位
  • 最佳获胜策略
  • 竞争仪錶板
  • 公司评估象限

第八章：关键参与者简介

  • Company A
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company B
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company C
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company D
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company E
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events

第九章：日本口服抗糖尿病药物市场-产业分析

  • 驱动因素、限制因素和机会
    • 概述
    • 驱动程式
    • 限制
    • 机会
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁
  • 价值链分析

第 10 章：附录

简介目录
Product Code: SR112025A15652

Japan oral anti-diabetic drug market size reached USD 2.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.7 Billion by 2033, exhibiting a growth rate (CAGR) of 4.42% during 2025-2033. The rising prevalence of diabetes, due to factors like changing lifestyles and the increasing obesity rates, is primarily driving the market growth.

Oral anti-diabetic drugs, pivotal in the management of type 2 diabetes, are pharmacological agents designed to regulate blood glucose levels in individuals whose bodies either resist the effects of insulin or don't produce enough. While insulin injections remain a primary treatment for diabetes, oral antidiabetic medications offer a non-invasive alternative and often serve as the first line of defense against the progression of the disease. These medications operate through various mechanisms, such as stimulating the pancreas to produce more insulin, reducing the liver's glucose production, or improving insulin sensitivity in body tissues.

Japan Oral Anti-Diabetic Drug Market Trends:

Japan's oral antidiabetic drug market is a critical segment of its healthcare industry, reflecting both the nation's advanced medical research capabilities and its demographic challenges. With an aging population and increasing urbanization, there's been a notable rise in lifestyle diseases, including type 2 diabetes. A distinctive driver in the regional market is the strong emphasis on research and development activities. The approval of innovative drug classes, such as DPP-4 inhibitors and SGLT2 inhibitors, has not only expanded treatment options but also offered improved glycemic control with reduced side effects. Another trend shaping the market is the growing inclination towards personalized medicine. Recognizing that diabetes manifests differently in individuals, there's a push towards tailoring treatments based on genetic, environmental, and lifestyle factors. Consequently, combination therapies, which use two or more antidiabetic drugs, are gaining traction to achieve better blood sugar control. Furthermore, the Japanese government's proactive stance on healthcare, with policies promoting regular health check-ups and early detection, indirectly boosts the oral antidiabetic drug market. By emphasizing preventive measures and timely intervention, the country not only addresses the immediate health needs but also mitigates long-term healthcare costs associated with diabetes-related complications. Apart from this, the introduction of treatment modalities is anticipated to propel the market growth over the forecasted period.

Japan Oral Anti-Diabetic Drug Market Segmentation:

Drugs Insights:

  • Biguanides
    • Metformin
  • Alpha-Glucosidase Inhibitors
  • Dopamine D2 Receptor Agonist
    • Bromocriptin
  • SGLT-2 inhibitors
    • Invokana (Canagliflozin)
    • Jardiance (Empagliflozin)
    • Farxiga/Forxiga (Dapagliflozin)
    • Suglat (Ipragliflozin)
  • DPP-4 inhibitors
    • Onglyza (Saxagliptin)
    • Tradjenta (Linagliptin)
    • Vipidia/Nesina (Alogliptin)
    • Galvus (Vildagliptin)
  • Sulfonylureas
  • Meglitinides

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan oral anti-diabetic drug market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan oral anti-diabetic drug market?
  • What is the breakup of the Japan oral anti-diabetic drug market on the basis of drugs?
  • What are the various stages in the value chain of the Japan oral anti-diabetic drug market?
  • What are the key driving factors and challenges in the Japan oral anti-diabetic drug?
  • What is the structure of the Japan oral anti-diabetic drug market and who are the key players?
  • What is the degree of competition in the Japan oral anti-diabetic drug market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Oral Anti-Diabetic Drug Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Oral Anti-Diabetic Drug Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Oral Anti-Diabetic Drug Market - Breakup by Drugs

  • 6.1 Biguanides
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Segmentation
      • 6.1.3.1 Metformin
    • 6.1.4 Market Forecast (2025-2033)
  • 6.2 Alpha-Glucosidase Inhibitors
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Forecast (2025-2033)
  • 6.3 Dopamine D2 Receptor Agonist
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2019-2024)
    • 6.3.3 Market Segmentation
      • 6.3.3.1 Bromocriptin
    • 6.3.4 Market Forecast (2025-2033)
  • 6.4 SGLT-2 inhibitors
    • 6.4.1 Overview
    • 6.4.2 Historical and Current Market Trends (2019-2024)
    • 6.4.3 Market Segmentation
      • 6.4.3.1 Invokana (Canagliflozin)
      • 6.4.3.2 Jardiance (Empagliflozin)
      • 6.4.3.3 Farxiga/Forxiga (Dapagliflozin)
      • 6.4.3.4 Suglat (Ipragliflozin)
    • 6.4.4 Market Forecast (2025-2033)
  • 6.5 DPP-4 inhibitors
    • 6.5.1 Overview
    • 6.5.2 Historical and Current Market Trends (2019-2024)
    • 6.5.3 Market Segmentation
      • 6.5.3.1 Onglyza (Saxagliptin)
      • 6.5.3.2 Tradjenta (Linagliptin)
      • 6.5.3.3 Vipidia/Nesina(Alogliptin)
      • 6.5.3.4 Galvus (Vildagliptin)
    • 6.5.4 Market Forecast (2025-2033)
  • 6.6 Sulfonylureas
    • 6.6.1 Overview
    • 6.6.2 Historical and Current Market Trends (2019-2024)
    • 6.6.3 Market Forecast (2025-2033)
  • 6.7 Meglitinides
    • 6.7.1 Overview
    • 6.7.2 Historical and Current Market Trends (2019-2024)
    • 6.7.3 Market Forecast (2025-2033)

7 Japan Oral Anti-Diabetic Drug Market - Competitive Landscape

  • 7.1 Overview
  • 7.2 Market Structure
  • 7.3 Market Player Positioning
  • 7.4 Top Winning Strategies
  • 7.5 Competitive Dashboard
  • 7.6 Company Evaluation Quadrant

8 Profiles of Key Players

  • 8.1 Company A
    • 8.1.1 Business Overview
    • 8.1.2 Product Portfolio
    • 8.1.3 Business Strategies
    • 8.1.4 SWOT Analysis
    • 8.1.5 Major News and Events
  • 8.2 Company B
    • 8.2.1 Business Overview
    • 8.2.2 Product Portfolio
    • 8.2.3 Business Strategies
    • 8.2.4 SWOT Analysis
    • 8.2.5 Major News and Events
  • 8.3 Company C
    • 8.3.1 Business Overview
    • 8.3.2 Product Portfolio
    • 8.3.3 Business Strategies
    • 8.3.4 SWOT Analysis
    • 8.3.5 Major News and Events
  • 8.4 Company D
    • 8.4.1 Business Overview
    • 8.4.2 Product Portfolio
    • 8.4.3 Business Strategies
    • 8.4.4 SWOT Analysis
    • 8.4.5 Major News and Events
  • 8.5 Company E
    • 8.5.1 Business Overview
    • 8.5.2 Product Portfolio
    • 8.5.3 Business Strategies
    • 8.5.4 SWOT Analysis
    • 8.5.5 Major News and Events

9 Japan Oral Anti-Diabetic Drug Market - Industry Analysis

  • 9.1 Drivers, Restraints and Opportunities
    • 9.1.1 Overview
    • 9.1.2 Drivers
    • 9.1.3 Restraints
    • 9.1.4 Opportunities
  • 9.2 Porters Five Forces Analysis
    • 9.2.1 Overview
    • 9.2.2 Bargaining Power of Buyers
    • 9.2.3 Bargaining Power of Suppliers
    • 9.2.4 Degree of Competition
    • 9.2.5 Threat of New Entrants
    • 9.2.6 Threat of Substitutes
  • 9.3 Value Chain Analysis

10 Appendix